Influence of ustekinumab on body weight of patients with psoriasis: an initial report

Abstract

Introduction

Many recent epidemiological studies have shown the influence of treatment with anti-TNF-α on body mass of patients with psoriasis but there are no reports in the literature on the influence of ustekinumab on that parameter.

Aim

To review the effect of ustekinumab therapy on body weight in patients with psoriasis.

Material and methods

The examined group consisted of 11 patients with psoriasis treated at the Department and Clinic of Dermatology in Olsztyn. Patients’ body mass and body mass index (BMI) were evaluated prior to the first administration of the ustekinumab dose and at week 28 of treatment (the day of the fourth dose).

Results

Body mass increase was determined in 7 patients (64%), on average by 2.27 kg (p < 0.05), and the BMI increased by 3.35% (p < 0.1).

Conclusions

Observing a correlation between ustekinumab application and body mass increase, similar to the treatment with anti-TNF-α preparations, an attempt was undertaken at explaining that correlation by analysing the role of IL-12 and IL-23 in psoriasis pathogenesis. IL-12 and IL-23, by influencing the naïve lymphocytes T and stimulating their diversification towards Th1 and Th17, also, indirectly, cause an increase in TNF-α and other cytokines production (IL-2, IFN-γ, IL-17, IL-10, IL-22). Ustekinumab will then have a significant influence on decreasing the production of cytokines, which are important for metabolism and body mass.

Introduction

Numerous studies confirm the correlation between obesity and psoriasis. Hypotheses are even formulated that obesity may be a factor in development of psoriasis. Body mass index (BMI) 26–29 kg/m² increases the risk of psoriasis slightly while obesity (BMI > 29 kg/m²) increases that risk by more than 2-fold [1]. Additionally, body mass reduction improves the development of the disease [2–4].

It is also found that in the case of obese patients, the therapy effectiveness decreases. Patients with psoriatic arthritis and accompanying obesity less frequently achieved the Minimal Disease Activity (MDA) under the influence of therapy [5]. It is also established that body mass reduction by 5–10% improves the therapeutic reaction of psoriatic lesions to treatment with cyclosporine A [6]. Similarly, in patients whose body mass increases during therapy, the efficacy of biological medical drugs is lower [7]. Hence, a recommendation of less caloric diet may be complementary in treatment of patients with psoriasis [6].

Until now, the influence of treatment with anti-TNF-α preparations on body mass of patients with psoriasis has been evaluated but there are no reports in the literature on the influence of ustekinumab on that parameter.

Aim

Analysis of body mass and BMI in patients treated with ustekinumab for psoriasis was the aim of the paper.

Material and methods

The examined group consisted of 11 patients with psoriasis treated at the Department and Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology in Olsztyn. The patients satisfied the criterion of medium severe and severe psoriasis PASI > 10, BSA > 10 and DLQI > 10 according to the EuCOTT (European Consensus Conference on Treatment Goals and Transitioning Treatments) [8]. Patients’ body mass and BMI were evaluated prior to the first administration of the ustekinumab dose and at week 28 of treatment, i.e. on the day of administration of the fourth dose of the drug.

Results

Body mass increase was determined in 7 patients (64%), on average by 2.27 kg (p < 0.05), and the BMI increased by 3.35% (p < 0.1) (Figure 1).

Figure 1.

Analysis of body mass of 11 patients treated with ustekinumab at week 28

Our results are similar to those reported by other authors evaluating body mass of patients with psoriasis treated with anti-TNF-α preparations at week 24 of therapy. Gisondi et al. observed the average body mass increase in patients receiving etanercept by 1.5 ±2.7 kg (n = 58), and those receiving infliximab by 2.5 ±3.3 kg (n = 40) (p = 0.004). The control group consisted of patients treated with methotrexate, for whom no significant body mass changes were found [9]. Similarly, Renzo et al. showed the average body mass increase by 2.6 ±3.2% in patients treated with etanercept (n = 28) and infliximab (n = 12) [10]. Saraceno et al. conducted the analysis of body weight for patients treated with anti-TNF-α at week 48 of therapy. The average body mass increases for patients receiving infliximab were 1.54 kg (p = 0.0001), adalimumab – 2.57 (p = 0.0014), and etanercept – 2.18 (p = 0.007) [11]. On the other hand, Prignano et al. observed no statistically significant body mass increase in patients receiving etanercept (54%) (n = 62) and infliximab (53%) (n = 36) [12].

Observing the correlation between ustekinumab application and body mass increase, similar to the treatment with anti-TNF-α preparations, an attempt was undertaken at explaining that correlation by analysing the role of IL-12 and IL-23 in psoriasis pathogenesis. The IL-12 and IL-23, by influencing the naïve lymphocytes T and stimulating their diversification towards Th1 and Th17, also, indirectly, cause an increase in TNF-α and other cytokines production (IL-2, IFN-γ, IL-17, IL-10, IL-22) [13–15]. Ustekinumab will then have a significant influence on decreasing the production of TNF-α [16], which is of particular importance for metabolism and body mass [7].

The TNF-α influence on metabolism is highly complex. Physiologically increased synthesis of that cytokine probably represents one of the mechanisms limiting further body mass increase in obese people. In the case of obese people, macrophages of visceral fatty tissue produce twice as much TNF-α as in the case of slim persons [17–19]. The TNF-α stimulates leptin synthesis, which, acting on the hypothalamus, leads to decreasing appetite and food intake [18, 19]. Moreover, by stimulating hypothalamus and increasing the activity of the sympathetic system, it stimulates thermogenesis increasing the energy expenditure [19]. The TNF-α also influences a muscular mass decrease (activation of ubiquitin and non-enzymatic proteolysis of muscle proteins) [20]. In the fatty tissue, stimulation of lipolysis and inhibition of lipogenesis as well as decreased synthesis of anabolic insulin-like growth factor 1 (IGF-1) are observed [7, 18, 19]. On the other hand, TNF-α is responsible for the phenomena supportive to obesity, such as insulin resistance development (inhibiting the activity of the insulin receptor and glucose transporting proteins GLUT-4), as well as secondary, compensational insulin level increase stimulating the hunger centre [19].

Hence, the application of preparations inhibiting the activity of TNF-α may directly (adalimumab, infliximab, etanercept) or indirectly (ustekinumab) contribute to a body mass increase in treated patients.

Briot et al. observed a body mass increase in patients with spondyloarthropathies (also psoriatic arthritis) treated with anti-TNF-α preparations. Nevertheless, the body mass increase concerned not only the fatty tissue but also the muscles and additionally bone mineralisation was observed. The increase in the insulin-like growth factor IGF-1, which shows anabolic activity was also observed [4]. Muscle tissue body mass increase might be caused by the return of the protein reserves. On the other hand, due to the patients’ life quality improvement, they can return to normal life activity and integrate with the society [7] (Figure 2).

Figure 2.

TNF-α influence on body mass

The activity of ustekinumab is based mainly on decreasing the number of lymphocytes Th17, and hence IL-17. Currently, numerous studies prove the role of that cytokine in metabolism disorders, but that role is not fully known yet and the results of studies are controversial. Studies by Sumarac-Dumanovic et al. showed an increased concentration of cytokines dependent on lymphocytes Th17 (IL-17 and IL-23) in obese women, without an increase in concentration of cytokines related to lymphocytes Th1 (IL-12, IFN-γ) [21]. On the other hand, Zúñiga et al. showed an inhibitory influence of IL-17 on adipogenesis and metabolism of glucose in mice. Its deficiency increases diet-induced obesity and accelerates fatty tissue accumulation [22]. Numerous studies suggest that Th17 and IL-17 represent the missing link between the inflammation condition, immunological reaction and obesity [23, 24]. Moreover, it is found that the concentrations of TNF-α and IL-17 are closely correlated [25]. Hence, decreasing the concentration of TNF-α under the influence of therapy with ustekinumab, coupled with the decrease in the concentration of IL-17, may influence body mass increase in the patients.

Lymphocytes Th17 are also the source of IL-10, which mitigates inflammatory processes induced by TNF-α, IL-6 and IL-1 and has a protective influence on vascular endothelium in people suffering from diabetes [25, 26]. It also has a significant influence on metabolic processes. Low levels of IL-10 are linked to the metabolic syndrome, BMI increase as well as insulin resistance and type 2 diabetes [27]. On the other hand, studies by Jung et al. showed an increase in IL-10 concentration in obese patients coupled with body mass reduction [26]. Hence, blocking of IL-10 secretion might predispose to body mass increase.